# Detailed Summary

The transcription provides an overview of T-Cell Prolymphocytic Leukemia (TPLL), highlighting crucial information regarding its diagnosis, survival statistics, cytogenetics, treatment options, and patient management.

1. **Diagnosis and Demographics**: TPLL has a median age at diagnosis of 61 years, indicating that it typically affects older adults.
2. **Survival Rates**: The median overall survival for patients diagnosed with TPLL is reported to be less than 2 years, underscoring the aggressive nature of the disease.
3. **Cytogenetic Findings**: Ninety percent of cases show rearrangements involving TCL1A, B, and MTCP1 genes. There is also a noted association with disruptions in the ATM gene.
4. **Treatment Approach**: For asymptomatic cases, the treatment approach includes watchful waiting. The first-line therapy mentioned is allogeneic stem cell transplant if the patient is in their first remission.
5. **Prophylaxis & Monitoring**: Patients require prophylaxis for potential infections like PCP and shingles, along with monitoring for cytomegalovirus (CMV) infections.
6. **Call to Action**: The transcript ends with a call to subscribe for more exam-related cases, suggesting an educational context for the content shared.

Overall, the transcription captures significant aspects of TPLL, emphasizing the necessity of appropriate treatment and monitoring strategies for managing the disease effectively.

Haematology, Morphology, FRCPath Exams

[Music] T-cell prolymphocytic leukemia (T-PLL). Median age at diagnosis: 61 years. Median overall survival: less than 2 years.

Flow cytometry: CD2 weak, CD3 weak, CD5 weak, CD7 weak. Variables: CD4 and CD8.

Cytogenetics: 90% show TCL1, AB, and MTCP1 rearrangements. Association with ATM gene disruption.

[Applause]

Treatment: Watchful waiting for asymptomatic cases.

[Applause]

First-line therapy: Alemtuzumab, transplant in first remission.

PCP and shingles prophylaxis is required. Also, CMV PCR monitoring.

An important case for FRCPATH exam. Please subscribe to the channel for more exam-related cases. You will not go without.

[Music]

My.

[Music]

A.

[Music]

T-Prolymphocytic leukaemia

[Music]
tastic leukemia TPL
[Music]
L median age at diagnosis 61 years
median overall survival less than 2
[Music]
years flowy tomet Tre cd2 pause CD3 week
pause cd5 pause cd7 PA variables CD4 and
cd8
[Music]
[Music]
[Music]
cytogenetics 90% show tcl1 a b and mtcp1
rearrangements association with ATM Gene
disruption
[Music]
[Music]
[Applause]
[Music]
treatment watchful waiting of a
symptomatic cases
[Music]
[Applause]
[Music]
first line therapy almp to zumb
transplant and first remission
[Music]
PCP and shingles prophylaxis is required
also C mvpc are monitoring
[Music]
[Music]
an important case for f FRC path
[Music]
exam Please Subscribe the channel for
more exam related cases
you will not go without
[Music]
[Music]
[Music]
[Music]
my
[Music]
[Music]
a
[Music]

Get Our Mobile App

T-Prolymphocytic leukaemia

Transcription